Interagency Patent Coordination and Improvement Act of 2025

When drug companies apply for patents, the Patent and Trademark Office sometimes lacks critical information that the FDA already has — like details about a drug's approval history or labeling changes. This bill creates a formal task force between the two agencies so patent examiners can access FDA data when reviewing pharmaceutical patents. The goal is to prevent questionable patents that can be used to block cheaper generic drugs from reaching the market. It includes safeguards for confidential business information and requires a report to Congress within four years on how well the system is working.